These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23133884)

  • 1. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
    Schwittay A; Schumann C; Litzenburger BC; Schwenke K
    MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
    Agbalaka A; Schwenke K; Litzenburger B
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
    Kern KU; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
    Schwittay A; Schumann C; Litzenburger BC; Schwenke K
    J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
    Lange T; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
    Richter U; Waldmann-Rex S; Lehmann U
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.
    Strick V
    Curr Med Res Opin; 2014 Oct; 30(10):2085-92. PubMed ID: 24983745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
    Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
    Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
    Schwittay A; Sohns M; Heckes B; Elling C
    Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
    Schwittay A
    MMW Fortschr Med; 2013 Jan; 155(1):64. PubMed ID: 23573727
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
    Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
    Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds].
    Kern KU; Vogelmann T; Tölle TR
    MMW Fortschr Med; 2022 Apr; 164(Suppl 6):19-27. PubMed ID: 35449488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
    Bagaphou TC; Cerotto V; Gori F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.